Literature DB >> 2681122

Penetration of ceftazidime into intracranial abscess.

H T Green1, M A O'Donoghue, M D Shaw, C Dowling.   

Abstract

The penetration of ceftazidime into intracranial abscess was investigated in nine patients receiving intravenous ceftazidime. Concentrations of antibiotic in pus were measured by a microbiological agar diffusion assay (12 samples) and high performance liquid chromatography (8 samples) at varying times following ceftazidime administration. Concentrations of ceftazidime varying between 2.7 and 27.0 mg/l were detected. The role of ceftazidime in the therapy of intra-cranial abscess of otogenic origin is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2681122     DOI: 10.1093/jac/24.3.431

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 2.  Central nervous system melioidosis in the pediatric age group: review.

Authors:  G Lakshmi Prasad; Pushpa Kini
Journal:  Childs Nerv Syst       Date:  2017-04-27       Impact factor: 1.475

Review 3.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

4.  Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans.

Authors:  J Sjölin; N Eriksson; P Arneborn; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

Review 5.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.